Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTEREST: Traumakine in ARDS
NCT02622724Phase 3Terminated
- Sponsor
- Faron Pharmaceuticals
- Start
- Dec 2015
- Primary completion
- May 2018
- Modality
- Cytokines & Interferons
- Countries
- 8
01
Overview
A Phase 3 trial of interferon beta-1a in acute respiratory distress syndrome (ARDS), sponsored by Faron Pharmaceuticals. Started Dec 2015; status: terminated.
02
Drugs
interferon beta-1a
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT02622724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02622724.